Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 4/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5216676 | 0.84 | CYP3A4 (0.47) | KMT2A | |
| SCHEMBL5216843 | 0.83 | MEN1 (0.47) | DAOGPR84MEN1KMT2AHTR6 | |
| SCHEMBL5215190 | 0.82 | DAO (0.49) | DAOGPR84MEN1KMT2AMET | |
| SCHEMBL5223001 | 0.79 | KMT2A (0.62) | DAOGPR84MEN1KMT2AHTR6 | |
| SCHEMBL6605700 | 0.77 | MEN1 (0.47) | GPR84MEN1KMT2AHTR6MET | |
| SCHEMBL3157223 | 0.74 | MET (0.53) | GPR84MEN1KMT2AHTR6MET | |
| SCHEMBL6600430 | 0.73 | DAO (0.50) | DAOMEN1KMT2AMET | |
| SCHEMBL12955373 | 0.72 | LMNA (0.68) | PARP1 | |
| SCHEMBL6607081 | 0.72 | KDM4E (0.49) | MEN1KMT2AHTR6METPARP1 | |
| SCHEMBL1586483 | 0.71 | DAO (0.44) | DAOPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1397350-B1 | ISOQUINOLINONE DERIVATIVES AS PARP INHIBITORS | KUDOS PHARM LTD (GB) | 2007-02-28 | — | — | EP | disclosed |
| EP-1397350-B1 | ISOQUINOLINONE DERIVATIVES AS PARP INHIBITORS | KUDOS PHARM LTD (GB) | 2007-02-28 | — | — | EP | disclosed |
| EP-1397350-A1 | ISOQUINOLINONE DERIVATIVES AS PARP INHIBITORS | Kudos Pharmaceuticals Limited (GB) | 2004-03-17 | — | — | EP | disclosed |
| US-6664269-B2 | Adminisetring isoquinolinone compounds for therapy of disease mediated by the enzyme poly(ADP- ribose)polymerase (\"PARP\") | MAYBRIDGE PLC (GB) | 2003-12-16 | — | — | US | disclosed |
| US-20030008896-A1 | Isoquinolinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2003-01-09 | — | — | US | disclosed |
| WO-2002090334-A1 | ISOQUINOLINONE DERIVATIVES AS PARP INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008896-A1 | Isoquinolinone derivatives | PARP1, PARP2, PARP3 | DAO 2461/4885ROCK1 2948/4885PDPK1 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.